Shots:

• The approval is based on P-III global pivotal Phase 3 LDL-C lowering program assessing NEXLETOL vs PBO in 3000+ patients corrected LDL-C lowering when used with moderate or high intensity statins.- NEJM
• The study resulted in well-tolerated results- providing an average of 18% PBO corrected LDL-C lowering when used with moderate or high intensity statins
• NEXLETOL is novel orally administered once daily ATP Citrate Lyase (ACL) inhibitor involved in lowering LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors

Click here to read full press release/ article | Ref: Globe Newswire | Image: Behance